Purpose: Dutasteride, which is licensed for symptomatic benign prostatic hyperplasia, has been associated with a lower progression rate of low risk prostate cancer. We evaluated the effect of dutasteride on prostate cancer volume as assessed by T2-weighted magnetic resonance imaging. Materials and Methods: In this randomized, double-blind, placebo controlled trial, men with biopsy proven, low-intermediate risk prostate cancer (up to Gleason 3 þ 4 and PSA up to 15 ng/ml) who had visible lesion of 0.2 ml or greater on T2-weighted magnetic resonance imaging sequences were randomized to daily dutasteride 0.5 mg or placebo for 6 months. Lesion volume was assessed at baseline, and 3 and 6 months with image guided biopsy to the lesion at study exit. The primary end point was the percent reduction in lesion volume over 6 months. This trial was registered with the European Clinical Trials register (EudraCT 2009-102405-18). Results: A total of 42 men were recruited between June 2010 and January 2012. In the dutasteride group, the average volumes at baseline and 6 months were 0.55 and 0.38 ml, respectively and the average reduction was 36%. In the placebo group, the average volumes at baseline and 6 months were 0.65 and 0.76 ml, respectively, and the average reduction was À12%. The difference in percent reductions between the groups was 48% (95% CI 27.4e68.3, p <0.0001). The Accepted for publication November 14, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
most common adverse event was deterioration in erectile function, which was 25% in men randomized to dutasteride and 16% in men randomized to placebo. Conclusions: Dutasteride was associated with a significant reduction in prostate cancer volume on T2-weighted magnetic resonance imaging compared to placebo.
Key Words: prostatic neoplasms, watchful waiting, magnetic resonance imaging, biopsy, dutasteride DUTASTERIDE is licensed for men with LUTS associated with benign prostatic enlargement. 1 When assessed in placebo controlled prostate cancer studies, dutasteride decreased the proportion of men diagnosed with prostate cancer by 22.8% over 4 years 2 and it was associated with lower rates of disease progression over 3 years in men on active surveillance. 3 MRI of the prostate allows for assessment of prostate cancer volume over time. 4, 5 We report the use of MRI to assess the effect of dutasteride on prostate cancer volume in men on active surveillance. 
MATERIALS AND METHODS

This investigator led MAPPED (Magnetic resonance imaging in Primary Prostate
Primary and Secondary Objectives
The primary objective was to evaluate the percent reduction in tumor volume, assessed by T2W MRI, following exposure to dutasteride 0.5 mg daily for 6 months compared to placebo.
Secondary objectives included the percent reduction in tumor volume at 3 months and on functional MRI sequences, namely DCE imaging and DWI. Prostate cancer typically shows rapid wash-in and washout on DCE imaging due to the increased vascularity of its highly permeable neovessels. DWI of prostate cancer typically shows restricted diffusion due to disorganized tissue structure, which is seen as high signal (bright areas) on high b-value imaging. 6 
Patient Population
The full study protocol has been published previously. 7 Eligible men met UK NICE 2008 active surveillance criteria (up to Gleason 3 þ 4 disease and PSA up to 15 ng/ml) 8 based on biopsy within the preceding 2 years. In addition, men were required to have a 0.2 ml or greater lesion on the standard of care T2-weighted MRI.
All eligible consented men underwent a study specific, standardized multiparametric 3 Tesla MRI. The images were reviewed by 1 study radiologist (CA or AK) to assess for the presence of a T2W lesion 0.2 ml or greater. When confirmed, the man was randomized to placebo or dutasteride 0.5 mg daily for 6 months. MRI was repeated at 3 and 6 months. Each MRI scan was reported separately by each of the study radiologists, who were blinded to treatment allocation.
An exit biopsy was offered to all men with 10 standard cores and additional cores targeted to the MRI lesion using visual registration. 9 Men were not rebiopsied for discordant histology at baseline to avoid post-biopsy artefact on the study MRI scans. The concordance among baseline histology, lesion on MRI and exit histology was assessed. PSA, renal and liver function, and adverse events were assessed at baseline, and 3 and 6 months.
Randomization and Masking
A total of 17 patients were required to complete each arm to detect a 20% reduction in tumor volume, assuming a common SD of 20.5%, 80% power and 5% statistical significance. To account for failure to complete, we aimed to recruit 21 men per arm. Men were individually randomized using block randomization with varying block sizes. The statistical team at UCL supplied UCL Hospital pharmacy with a randomization list to allocate study medication. Patients, study physicians, radiologists and histopathologists were blinded to treatment allocation. radiologists and histopathologists were also blinded to PSA results.
Outcomes and Statistical Analysis
The primary outcome was the percent reduction in tumor volume between baseline and 6 months on T2-weighted imaging. This was calculated using the equation, (baseline volume e 6-month volume)/baseline volume Â 100, where baseline volume and 6 months volume were the average of the measurements made by the 2 raters. This percent reduction was compared between the dutasteride and placebo groups using the t-test with statistical significance set at p ¼ 0.05.
The secondary outcome of the percent reductions in tumor volume as measured by DCE imaging and DWI at 6 months were compared between the dutasteride and placebo groups using the t-test. Each analysis was repeated for the percent reduction in tumor volume at 3 months.
RESULTS
A total of 56 men consented to the study after meeting eligibility criteria based on standard of care MRI, histology and blood tests. Seven men were excluded as the study PSA or renal function did not meet the eligibility criteria. A study MRI scan was done in 49 men, of whom 7 were excluded due to MRI criteria. The remaining 42 men were randomized between June 2010 and January 2012. Figure 1 shows the CONSORT 10 diagram. A total of 21 men were randomized to each group (table 1) . One man exited the dutasteride group prior to taking any study medication as he wished to conceive a child. Another man exited the placebo group to receive active treatment in response to upgrading from Gleason 3 þ 3 to 3 þ 4 at the UCL Hospital pathology review. The primary end point was derived in 20 men in each group.
When the baseline scans were formally reported, it was noted that 11 of 42 randomized men had Figure 1 . CONSORT 10 diagram shows men in study lesions that measured less than 0.2 ml on T2-weighted images by 1 and both study radiologists (5 and 6 patients, respectively). All of these men had a lesion volume of 0.2 ml on other sequences (DCE and diffusion weighted imaging) as determined by at least 1 of the radiologists. One of the men was deemed to have a visible lesion by 1 radiologist but not by the other. Eight men had a mean lesion volume of less than 0.2 ml on T2-weighted imaging. These men were included in the analysis as they had met the original inclusion criterion (1 study radiologist assessing the MRI scan as showing a 0.2 ml lesion on MRI). The agreement in volume assessment between the 2 raters was formally assessed.
Primary Outcome (Total Tumor Volume Change on T2-Weighted Magnetic Resonance Imaging over 6 Months) In the dutasteride group, the average volume at baseline and 6 months was 0.55 and 0.38 ml, respectively, and the average reduction was 36% (table 2). In the placebo group, the average volume at baseline and 6 months was 0.65 and 0.76 ml, respectively, and the average reduction was À12% (ie 12% growth). The difference in reduction between the groups was 48% (95% CI 27.4e68.3, p <0.0001, fig. 2 ). Of the 20 men randomized to dutasteride 15 (75%) had a reduction in tumor volume and 5 (25%) had stability, defined as less than a 20% volume change. No man randomized to dutasteride had an increase in tumor volume. In contrast, 2 men (10%) in the placebo group had a reduction in volume, 13 (65%) were stable and 5 (25%) exhibited an increase of greater than 20% ( fig. 3 ).
Secondary Outcomes
Tumor Volume Change on Functional Imaging over 6
Months. On DCE imaging, men randomized to dutasteride had a 42.3% reduction in tumor volume at 6 months compared to a 4.2% reduction in men randomized to placebo, representing a 38% mean difference between the groups (95% CI 16.59e59.64, p ¼ 0.001, table 2). On diffusion weighted imaging, men randomized to dutasteride had a 33% reduction in tumor volume at 6 months compared to a 7% increase in the men randomized to placebo, conferring a mean difference between the groups of 40% (95% CI 21.31e59.63, p ¼ 0.0001).
Tumor Volume Change over 3 Months on T2-Weighted
Imaging. At 3 months there was a 34% reduction in tumor volume in the dutasteride group compared to 0.21% in the placebo group, representing a mean difference between the groups of 34% (95% CI 21e47, p 0.0001).
Prostate Volume Change. The average percent reduction in prostate volume at 6 months was 15% in the dutasteride group compared to an increase of 3.3% in the placebo group, representing a mean difference between the groups of 18.8% (95% CI 14.9e22.8, p <0.0001).
Agreement between Raters. The agreement between the raters was investigated using a Bland-Altman plot based on the percent reduction in tumor volume calculated separately for each individual rater (supplementary figure, http://jurology.com/).
In addition, analysis of the primary outcome was repeated for each rater separately (supplementary table 1, http://jurology.com/). One patient was Figure 2 . Percent change in total tumor volume of all 40 patients between baseline and 6 months as measured on T2-weighted imaging. Figure 3 . a, in 68-year-old man lesion in left peripheral zone (arrow) was seen as low signal on T2W imaging at baseline (A). It was reduced at 3 months (B) and further at 6 months (C ) after 6 months of daily dutasteride 0.5 mg. On DWI baseline scan shows high signal lesion with smaller volume than T2W lesion (D). At 3 (E ) and 6 (F ) months this had decreased in size, although to lesser extent than reduction evident on T2W imaging and DWI. DCE images at baseline showed enhancing lesion in left peripheral zone (G), which was reduced in volume at 3 (H ) and 6 (I ) months. b, 71-year-old man in placebo group had right peripheral zone lesion at baseline on T2W imaging (A), which was stable at 3 (B) and 6 (C ) months. Lesion was seen as high signal on DWI at baseline (D) and it was stable at 3 (E ) and 6 (F ) months. Lesion was enhanced on DCE images at baseline (G). While it was less conspicuous at 3 months (H ), it was stable at 6 months (I ).
deemed by 1 rater to have an increase in volume and the other rater to have a reduction in volume, which had a significant effect on the results of rater 1. Supplementary table 1, http://jurology.com/) shows the analysis with and without this outlier. The results were consistent across the raters, although rater 1 recorded a larger volume reduction than rater 2.
Histological Data. All men were offered an end of study biopsy, although 12 of 40 declined. Histological upgrading to Gleason 4 þ 3 or greater was seen in 3 of 15 men (20%) in the dutasteride group and in 6 of 13 (46%) in the placebo group (supplementary table 2, http://jurology.com/).
Magnetic Resonance Imaging Lesions and Histology
Concordance. Of 40 men 37 had histological confirmation of the MRI lesion at baseline or exit (supplementary table 3, http://jurology.com/). The remaining 3 men had discordant baseline histology, of whom 1 had a negative exit biopsy (placebo group) and 2 declined the exit biopsy. One of the latter men was in the placebo group and 1 was in the dutasteride group.
Prostate Specific Antigen Changes. In men on placebo, the direction of change in PSA mirrored the direction of change in tumor volume (supplementary  table 4 , http://jurology.com/). All men on dutasteride showed a PSA reduction with no clear correlation between the change in lesion volume and PSA.
Medication Compliance. All men were compliant with medication according to the returned tablet count at the end of each 3-month prescription period.
Adverse Events. No serious adverse events occurred and no subject discontinued study medication due to adverse events. Deterioration of sexual function, defined as at least a 4-point reduction on IIEF-15 (International Index of Erectile Function), 
DISCUSSION
Dutasteride 0.5 mg daily was associated with an average reduction in prostate cancer volume of 36%, compared to an average increase of 12% in men on placebo, as assessed by T2W-MRI over 6 months.
This volume change was associated with less histological upgrading at targeted biopsy on study exit when randomized to dutasteride than to placebo (20% vs 46%). However, the lack of targeted biopsies at baseline to match to targeted exit biopsies and the small sample size limit the ability to definitively ascribe this to the effect of dutasteride. The rate of upgrading in the placebo group was high compared to that seen in men undergoing scheduled repeat standard 10 to 12-core systematic biopsy on active surveillance protocols. 12 However, this was expected due to the use of image guided targeting as well as the standard biopsy exit, compared to standard biopsy alone at entry, in the majority. 13 In 3 of 40 men there was a lack of concordance between biopsy and entry histology, which was not resolved on targeted biopsy at exit, which may represent a false-positive MRI lesion. However, because 2 of the men declined the exit biopsy, this could not be confirmed.
There have been concerns that dutasteride may act selectively on low grade tumors and may be associated with a greater likelihood of developing high grade cancers.
14 However, radical prostatectomy data from randomized studies have not confirmed this concern. 15 In our study, 2 men randomized to dutasteride had 1 and 2 mm of Gleason 4 þ 4, respectively, on targeted biopsy at exit, with an overall Gleason grade of 3 þ 4. At entry, the first had 9 mm Gleason 3 þ 3 on standard transrectal biopsy, with a lesion volume of 0.97 ml, which reduced to 0.64 ml at 6 months. The second had 4 mm 3 þ 4 on targeted biopsy at entry, with a lesion volume of 0.20 ml, which reduced to 0.13 ml at 6 months. This grade increase on targeted biopsy at exit would be compatible with the grade shift seen with a targeted biopsy approach. 16 A dutasteride associated reduction in prostate cancer volume was seen at 3 months, with a marginal additional reduction by 6 months. The time scale was similar to that of the prostate volume reduction in LUTS studies. We noted a greater proportional reduction in tumor volume compared to whole prostate volume, which suggests that prostate cancer may be more sensitive to androgen depletion than noncancerous prostate tissue.
The functional MRI sequences (DCE and DWI) assess perfusion and cell density, respectively. The percent volume reduction in functional sequences was similar to that on T2W imaging, although DWI tumor volumes were lower than on other sequences.
The adverse event profile was compatible with the known side effects of dutasteride. Significantly more men taking dutasteride (25% vs 16%) showed deterioration in sexual function.
The study is limited in both its sample size and duration. The 20% threshold for a reduction in tumor volume change was chosen as it was the least change that might be considered clinically meaningful and assessable by our independent observers. Sufficient men were recruited to achieve a power of 80% to detect a 20% volume change. A 6-month interval of assessment, which is common in many active surveillance protocols, 12 and is known to show a response to dutasteride in studies of men with LUTS. The fact that a study of this size and duration could meet its primary end point is promising for future exploratory studies of this type.
Another limitation of the study relates to the external validity of the study population. The eligibility criteria consisted of the UK NICE 2008 criteria for active surveillance in men with low or intermediate risk disease (Gleason sum 7 or less, PSA 15 ng/ml or less and clinical T2b disease). Of note, these criteria do not include any estimation of burden of disease, such as the number of cores positive, maximum cancer core length or percent cancer core involvement. In addition to the UK NICE criteria, men were required to have a lesion visible on T2W MRI.
Men with lesions seen exclusively on functional imaging were excluded. We do not know whether radiological phenotype predicts prognosis or responsiveness, although men with no visible lesion on MRI are at lower risk for progression than men with a visible lesion. 17 We assessed for an imbalance of tumor size in each group, which might have led to a spurious result if larger tumors are assumed to have a greater growth rate. Four men had a tumor volume of greater than 1 ml, of whom 3 were randomized to placebo. We repeated the analysis with these men removed and found similar results. In addition, a formal analysis adjusted for baseline volume was performed with little change in the outcome.
Our findings may have important clinical implications. 1) If MRI reliably detects a prostate cancer volume change, it could be useful for reassessment during surveillance. 18 Further work is needed to determine the imaging parameters (rate of change or an absolute threshold) at which transition to active treatment should be initiated, as recommended in the recent PRECISE (Prostate Cancer Radiological Estimation of Change in Sequential Evaluation) guidelines. 19 2) This novel design might be useful for assessing well tolerated agents that might modify the natural history of prostate cancer (eg aspirin, vitamin D and dietary modifications, including cruciferous vegetables 20e22 ). To date, large and expensive epidemiological studies of long duration 20 using repeat random biopsies in men on active surveillance 21 have been used. Our novel study design could allow for initial screening of potential agents for further study.
CONCLUSIONS
Dutasteride is associated with a reduction in prostate cancer volume, as assessed by T2W MRI in men with biopsy proven low or intermediate risk prostate cancer suitable for active surveillance, over a 6-month period. This novel image based study design may be of use in assessing the response to other well tolerated interventions in men on active surveillance.
